Moderna's leaked phase 3 cancer-vaccine data showed a 42% reduction in recurrence/death risk vs 40% expected; some hoped for above 50%, and survival data had not leaked. The stock fell partly after a sharp prior rise; the speaker calls the leaked results overall positive, pending final results due end of week.

Okay, let's move on to talking about a big stock in the Nasdaq index. Not so much today, but yesterday. This is the company "Moderna". It's a completely different story from technology stock trading here.

There was a lot of optimism ahead of what would happen this weekend. We are supposed to get the results of the cancer vaccine trials. We have obtained the first stage and the second stage.

There was a leak yesterday that caused the stock to drop. Tell us about some of the price movements that are happening here.

Yes, we see that the company lost approximately $17.2 billion in market value because of this report. The data was previously published by a news site specializing in oncology ahead of the European Society for Medical Oncology (ESMO) meeting that we will be seeing this weekend.

The initial results were presented from a major phase 3 trial attempting to mitigate or even reduce the recurrence of cancer and similar conditions . Therefore, the results of the experiment were mostly good.

The risk of recurrence or death has been reduced by 42%. Expectations on Wall Street were at 40%. It appears that there are some investors who have higher hopes that this figure will exceed the 50% mark, and they have not yet seen the survival data that has not yet been leaked.

This may also be a driving factor for this stock , but the results seem to meet market expectations to some extent. I think there is a class of investors who are looking for more than that, even a cancer treatment from Moderna.

Unfortunately, we see the stocks heading downwards, but overall this seems to have been positive news in terms of the leaks and results that were presented. Part of that may be due to how high the stock price had risen before this event; Everyone wants a cure for cancer, and this was a step in the right direction when we got the results of the first and second phases of the trial, wasn't it?

And so, perhaps, the news. We'll see when we get the actual final results at the end of this week.

Let's talk about oil now, as we see Moderna's stock down by about 3.5% in pre-market trading, pushing it down further. Not as dramatic as yesterday, when the movement was at 17%, although it ended the session above its lowest levels.